FDA Sniffs Asthma Drugs Over Child Safety Concerns

Law360, New York (November 26, 2007, 12:00 AM EST) -- Safety officials at the Food and Drug Administration will meet this week to discuss the rare, but potentially fatal, side effects of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair in children.

The advisory panel, which will meet from Tuesday to Thursday of this week, comes after a scathing October report in which FDA staff concluded that the two asthma medications, as well as Novartis' Foradil, may have “an unfavorable risk-benefit ratio” for children's asthma.

The drugs contain the active ingredient salmeterol which may cause adverse...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.